07:00 Mon 25 Nov 2019
Shield Therapeutics - QCA Corporate Governance Code
("Shield" or the "Group")
The Company does not intend to make any changes to its Board composition or to the constitution and membership of its Audit, Nomination and Remuneration Committees as a consequence of the adoption of the QCA Code.
Commenting,
"High standards of corporate governance are fundamental to the continued growth and development of Shield. The Board and its committees play a key role in ensuring these high standards are supported through internal frameworks, policies and procedures for the long-term benefit of our shareholders."
Our website www.shieldtherapeutics.com will contain further details on how we comply with the QCA Code.
For further information please contact:
|
|
|
+44 (0)20 7186 8500 |
|
|
|
|
Nominated Advisor and Joint Broker |
|
|
|
|
+44 (0)20 7418 8900 |
Joint Broker finnCap Ltd |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus/Lianne Cawthorne |
+44 (0)7980 541 893 / +44 (0)7584 391 303 |
About
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group's lead product, Feraccru®/ AccruferTM has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE